Clinical effects of ulinastatin and thymosis α1 on immune-modulation in septic patients

Chinese Critical Care Medicine

Volumn 21, Issue 3, 2009, Pages 147-150

  Su, Lei ^a   Meng, Fan Su ^a   Tang, You Qing ^a   Wen, Qiang ^a   Liu, Yun Song ^a   Tang, Li Qun ^a   Duan, Peng Kai ^a   Luo, Rui Jun ^a  

^a GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

Author keywords

CD14+ monocyte; Helper T lymphocyte; Human leucocyte antigen DR; Immuno modulation; Sepsis; Thymosin 1; Ulinastatin

Indexed keywords

CD14 ANTIGEN; CD4 ANTIGEN; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; THYMOSIN ALPHA1; ULINASTATIN;

ADULT; ANTIBIOTIC THERAPY; ANTIGEN EXPRESSION; APACHE; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUID RESUSCITATION; HUMAN; IMMUNOMODULATION; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; SEPSIS; TH1 CELL; TH2 CELL;

ADULT; AGED; ANTIGENS, CD14; FEMALE; GLYCOPROTEINS; HLA-DR ANTIGENS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-4; INTERLEUKIN-6; MALE; MIDDLE AGED; SEPSIS; T-LYMPHOCYTES, HELPER-INDUCER; THYMOSIN;

EID: 64249123043     PISSN: 10030603     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.1003-0603.2009.03.006     Document Type: Article

References (12)

1. Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med, 1996,24(7):1125-1128.
2. Bone RC. Immunologic dissonance: a continuing evolution in our understanding of systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med, 1996,125(8):680-687.
3. Hicks P, Cooper DJ, the Australian and New Zealand Intensive Care Society (ANZICS) Board and Clinical Trials Group Executive Committee. The Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Resusc, 2008,10(1):8.
4. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsts Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med, 2004,32(3):858-873.
5. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest, 1992,101(6):1644-1655.
6. Chinese source.
7. Chinese source.
8. Chinese source.
9. Chinese source.
10. Venet F, Tissot S, Debard AL, et al. Decreased monocyte human leukocyte antigen-DR expression after severe burn injury: correlation with severity and secondary septic shock. Crit Care Med, 2007,35(8):1910-1917.
11. Chinese source.
12. Chinese source.